CalciMedica CFO Stephen Bardin Resigns; Departure Effective After Q3 10-Q Filing
CALC is trading near its 52-week low of $1.03 (1.0% above the low) on light trading volume (0.2× avg).
Summary
CalciMedica's CFO resigned effective immediately after the Q3 10-Q is filed, leaving the cash-strapped, going-concern-flagged company without a named successor while it leans on its ATM program for funding.
Key Events · Executive and Board Changes · CALC
-
CFO Resigns
Stephen Bardin, CFO and principal accounting and financial officer, gave notice on October 15, 2026, effective immediately after the Q3 2026 Form 10-Q is filed.
-
No Successor Named
The filing names no replacement or interim CFO, leaving the principal financial and accounting officer roles vacant once the 10-Q is filed.
-
Company States No Disagreement
CalciMedica says the resignation was to pursue another professional opportunity and was not due to any disagreement with the company.
-
Timing Against Capital Needs
The departure lands while the company carries a going-concern warning, roughly $18.6M in cash, and a $25M at-the-market program activated September 30, 2026.
Analysis · CALC · Life Sciences
CalciMedica's CFO, principal accounting officer and principal financial officer is leaving, with his resignation effective immediately after the company files its Q3 2026 Form 10-Q. That timing matters: the company is operating under a going-concern warning with roughly $18.6M in cash, is relying on a $25M at-the-market program activated in late September, and just completed a 1-for-5 reverse split to hold its Nasdaq listing. Losing the person responsible for the books and the capital-raising mechanics at that moment leaves a gap in financial leadership while the company still needs to raise money. The filing states the resignation was not due to any disagreement with the company, and no successor or interim CFO has been named in this filing.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $1.03 to $36.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.